免疫检查点抑制剂相关甲状腺功能异常的临床特征及影响因素
该回顾性研究纳入2019年1月至2021年12月在南昌大学第二附属医院接受免疫检查点抑制剂(ICI)治疗的肿瘤患者560例,中位随访11.0个月,ITD发生率为50.7%。基线TSH水平(OR,1.935/mcIU/L;95%CI,1.613-2.321;P<.001)和联合靶向治疗(OR,2.101;95%CI,1.433-3.079;P<.001)与ITD发生最强相关。未发生ITD的患者总生存显著低于发生ITD者(HR,0.523;95%CI,0.599-0.97;P<.001)。
要点
- ICI治疗患者ITD发生率为50.7%,中位发生时间73(34.5-149)天。
- 基线TSH水平及联合靶向治疗与ITD发生独立相关。
- 未发生ITD者总生存显著低于发生ITD者(HR,0.523)。
核心结论
- ICI相关ITD发生率高,病程变化快,接受免疫治疗的患者应监测甲状腺功能以及时发现ITD并早期干预。
研究设计与样本
- 回顾性研究,纳入2019年1月至2021年12月在南昌大学第二附属医院接受ICI治疗的肿瘤患者,按是否发生甲状腺功能异常分为ITD组和非ITD组,共560例符合标准,中位随访11.0个月。
主要发现
- ITD发生率为50.7%。
- 基线TSH水平(OR,1.935/mcIU/L;95%CI,1.613-2.321;P<.001)和联合靶向治疗(OR,2.101;95%CI,1.433-3.079;P<.001)与ITD发生最强相关。
- 接受ICI药物治疗的患者ITD中位发生时间为73(34.5-149)天。
- 初诊为甲状腺功能亢进型ITD的87例患者中,46例(52.9%)在病程中进展为甲状腺功能减退。
- 基线抗甲状腺球蛋白抗体异常与ITD发生强相关(OR,67.393;95%CI,5.637-805.656;P=.001)。
临床怎么用
- 作者认为,接受免疫治疗的患者应监测甲状腺功能,以发现ITD并允许早期干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Explore the clinical characteristics and influencing factors of immune thyroid dysfunction (ITD) caused by immune checkpoint inhibitors (ICIs) in the treatment of malignant tumors. METHODS: This was a retrospective study of cancer patients treated with ICIs between January 2019 and December 2021 at the Second Affiliated Hospital of Nanchang University. According to the occurrence of thyroid dysfunction, patients were divided into an ITD group and non-ITD group. We describe the clinical characteristics, autoantibody levels, and their impact on prognosis of patients with ICI-related ITD. RESULT: A total of 560 cases meeting the criteria were included, with a median follow-up time of 11.0 months. The incidence of ITD was 50.7%. Baseline TSH levels (OR, 1.935/mcIU/L; 95% CI, 1.613-2.321; P < .001) and combination targeted therapy (OR, 2.101; 95% CI, 1.433-3.079; P < .001) were most strongly associated with the occurrence of ITD. The median time to ITD in patients receiving medication with ICIs was 73 (34.5-149) days. Of the 87 patients initially diagnosed with hyperthyroid ITD, 46 (52.9%) progressed to hypothyroidism over the course of the disease. Baseline anti-thyroglobulin antibody abnormalities were strongly associated with the occurrence of ITD (OR, 67.393; 95% CI, 5.637-805.656; P = .001). Overall survival was significantly lower in patients who did not develop ITD than in those who did (hazard ratio, 0.523; 95% CI, 0.599-0.97; P < .001). CONCLUSION: The incidence of ICI-related ITD is high, and the course of the disease is rapidly changing, and thyroid function in patients treated with immunotherapy should be monitored to detect ITD and permit early intervention.
引用
- Zhang Q, Jiao X, Lai X, et al. Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction. J Clin Endocrinol Metab. 2023. PMID: 37183427. doi:10.1210/clinem/dgad260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。